Peter C. Cook, Sheila L. Brown, Emma L. Houlder, Julio Furlong-Silva, Daniel P. Conn, Stefano A. P. Colombo, Syed Baker, Freya R. Svedberg, Gareth Howell, Margherita Bertuzzi, Louis Boon, Joanne E. Konkel, Christopher R. Thornton, Judith E. Allen, Andrew S. MacDonald
{"title":"Mgl2+ cDC2s coordinate fungal allergic airway type 2, but not type 17, inflammation in mice","authors":"Peter C. Cook, Sheila L. Brown, Emma L. Houlder, Julio Furlong-Silva, Daniel P. Conn, Stefano A. P. Colombo, Syed Baker, Freya R. Svedberg, Gareth Howell, Margherita Bertuzzi, Louis Boon, Joanne E. Konkel, Christopher R. Thornton, Judith E. Allen, Andrew S. MacDonald","doi":"10.1038/s41467-024-55663-3","DOIUrl":null,"url":null,"abstract":"<p>Fungal spores are abundant in the environment and a major cause of asthma. Originally characterised as a type 2 inflammatory disease, allergic airway inflammation that underpins asthma can also involve type 17 inflammation, which can exacerbate disease causing failure of treatments tailored to inhibit type 2 factors. However, the mechanisms that determine the host response to fungi, which can trigger both type 2 and type 17 inflammation in allergic airway disease, remain unclear. Here we find that CD11c<sup>+</sup> DCs and CD4<sup>+</sup> T cells are essential for development of both type 2 and type 17 airway inflammation in mice repeatedly exposed to inhaled spores. Single cell RNA-sequencing with further multi-parameter cytometry shows that allergic inflammation dramatically alters the proportion of numerous DC clusters in the lung, but that only two of these (Mgl2<sup>+</sup> cDC2s and CCR7<sup>+</sup> DCs) migrate to the dLNs. Targeted removal of several DC subsets shows that Mgl2<sup>+</sup> cDC2 depletion reduces type 2, but not type 17, fungal allergic airway inflammation. These data highlight distinct DC subsets as potential therapeutic targets for the treatment of pulmonary fungal disease.</p>","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"74 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-024-55663-3","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Fungal spores are abundant in the environment and a major cause of asthma. Originally characterised as a type 2 inflammatory disease, allergic airway inflammation that underpins asthma can also involve type 17 inflammation, which can exacerbate disease causing failure of treatments tailored to inhibit type 2 factors. However, the mechanisms that determine the host response to fungi, which can trigger both type 2 and type 17 inflammation in allergic airway disease, remain unclear. Here we find that CD11c+ DCs and CD4+ T cells are essential for development of both type 2 and type 17 airway inflammation in mice repeatedly exposed to inhaled spores. Single cell RNA-sequencing with further multi-parameter cytometry shows that allergic inflammation dramatically alters the proportion of numerous DC clusters in the lung, but that only two of these (Mgl2+ cDC2s and CCR7+ DCs) migrate to the dLNs. Targeted removal of several DC subsets shows that Mgl2+ cDC2 depletion reduces type 2, but not type 17, fungal allergic airway inflammation. These data highlight distinct DC subsets as potential therapeutic targets for the treatment of pulmonary fungal disease.
期刊介绍:
Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.